IQENLOS Trademark

Trademark Overview


On Monday, October 25, 2021, a trademark application was filed for IQENLOS with the United States Patent and Trademark Office. The USPTO has given the IQENLOS trademark a serial number of 97090919. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Thursday, June 12, 2025. This trademark is owned by Eli Lilly and Company. The IQENLOS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases
iqenlos

General Information


Serial Number97090919
Word MarkIQENLOS
Filing DateMonday, October 25, 2021
Status734 - FIFTH EXTENSION - GRANTED
Status DateThursday, June 12, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 2, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, November 8, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Thursday, October 28, 2021NEW APPLICATION ENTERED
Monday, November 8, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, June 27, 2022ASSIGNED TO EXAMINER
Wednesday, June 29, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 13, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 2, 2022PUBLISHED FOR OPPOSITION
Thursday, February 9, 2023SOU TEAS EXTENSION RECEIVED
Thursday, February 9, 2023SOU EXTENSION 1 FILED
Thursday, February 9, 2023SOU EXTENSION 1 GRANTED
Tuesday, August 2, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 27, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Saturday, February 11, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 22, 2023SOU EXTENSION 2 FILED
Tuesday, August 22, 2023SOU EXTENSION 2 GRANTED
Thursday, August 24, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 13, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, February 13, 2024SOU EXTENSION 3 GRANTED
Wednesday, February 14, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 15, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, August 22, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, February 13, 2024SOU EXTENSION 3 FILED
Thursday, August 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 15, 2024SOU EXTENSION 4 FILED
Thursday, August 15, 2024SOU EXTENSION 4 GRANTED
Monday, February 17, 2025SOU EXTENSION 5 FILED
Tuesday, February 18, 2025SOU TEAS EXTENSION RECEIVED
Tuesday, June 3, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, June 12, 2025SOU EXTENSION 5 GRANTED